Combination of Tetrandrine with cisplatin enhances cytotoxicity through growth suppression and apoptosis in ovarian cancer in vitro and in vivo

Cancer Letters

Volumn 304, Issue 1, 2011, Pages 21-32

  Zhang, Yuxing ^a,b   Wang, Chao ^a,b   Wang, Haiwei ^a,b   Wang, Kankan ^a   Du, Yanzhi ^a   Zhang, Ji ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

Cisplatin; Ovarian cancer; Subcutaneous tumor model; Tetrandrine; Wnt cadherin

Indexed keywords

CISPLATIN; TETRANDRINE;

ADD ON THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZYLISOQUINOLINES; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; CISPLATIN; DRUG SYNERGISM; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, INBRED BALB C; MICE, NUDE; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 79952251376     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.01.022     Document Type: Article

References (44)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer 2001, 94:153-156.
2. Lhomme C., Morice P., Planchamp F., Darai E., Joly F., Leblanc E., Lefranc J.P., Querleu D. Clinical practice guidelines 2008 for the surgical treatment, medical first-line and consolidation treatments of patients with epithelial ovarian cancer - update according to the methodology of Standards, Options: Recommendations (SOR). Bull Cancer 2008, 95:881-886.
3. Harries H.M.G.M. Part I: Chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. Lancet Oncology 2002, 3:529-536.
4. Ahmedin Jemal R.S., Ward Elizabeth, Hao Yongping, Xu Jiaquan, Thun Michael J. Cancer statistics, 2009. CA Cancer J. Clin. 2009, 59:225-249.
5. Yoshizumi N., Fujiwara J., Yoshizaki A., Sato M., Sakai R., Nishiya I. Cytokinetic effects of carboplatin and cisplatin on a human ovarian cancer cell line. Hum Cell 1988, 1:301-307.
6. Launay-Vacher V., Rey J.B., Isnard-Bagnis C., Deray G., Daouphars M. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother. Pharmacol. 2008, 61:903-909.
7. Stewart D.J. Mechanisms of resistance to cisplatin and carboplatin. Crit. Rev. Oncol. Hematol. 2007, 63:12-31.
8. Ho J.W., Leung Y.K., Chan C.P. Herbal medicine in the treatment of cancer. Curr. Med. Chem. Anticancer Agents 2002, 2:209-214.
9. Ho L.J., Chang D.M., Chang M.L., Kuo S.Y., Lai J.H. Mechanism of immunosuppression of the antirheumatic herb TWHf in human T cells. J. Rheumatol. 1999, 26:14-24.
10. Li S.Y., Ling L.H., Teh B.S., Seow W.K., Thong Y.H. Anti-inflammatory and immunosuppressive properties of the bis-benzylisoquinolines: in vitro comparisons of tetrandrine and berbamine. Int. J. Immunopharmacol. 1989, 11:395-401.
11. Shen Y.C., Chen C.F., Sung Y.J. Tetrandrine ameliorates ischaemia-reperfusion injury of rat myocardium through inhibition of neutrophil priming and activation. Br J Pharmacol 1999, 128:1593-1601.
12. Li S.Y., Teh B.S., Seow W.K., Ling L.H., Thong Y.H. Effect of tetrandrine on immunological responses and cardiac transplant rejection in mice. Int. Arch. Allergy Appl. Immunol. 1989, 90:169-173.
13. Liu Q.Y., Karpinski E., Rao M.R., Pang P.K. Tetrandrine: a novel calcium channel antagonist inhibits type I calcium channels in neuroblastoma cells. Neuropharmacology 1991, 30:1325-1331.
14. Lin T.Y., Tseng S.H., Li S.J., Chen J.C., Shieh J.S., Chen Y. Tetrandrine increased the survival rate of mice with lipopolysaccharide-induced endotoxemia. J Trauma 2009, 66:411-417.
15. Koh S.B., Ban J.Y., Lee B.Y., Seong Y.H. Protective effects of fangchinoline and tetrandrine on hydrogen peroxide-induced oxidative neuronal cell damage in cultured rat cerebellar granule cells. Planta Med 2003, 69:506-512.
16. Chen Y.J. Potential role of tetrandrine in cancer therapy. Acta Pharmacol Sin 2002, 23:1102-1106.
17. Chen Y., Chen J.C., Tseng S.H. Effects of tetrandrine plus radiation on neuroblastoma cells. Anticancer Res 2009, 29:3163-3171.
18. Sun X., Xu R., Deng Y., Cheng H., Ma J., Ji J., Zhou Y. Effects of tetrandrine on apoptosis and radiosensitivity of nasopharyngeal carcinoma cell line CNE. Acta Biochim. Biophys. Sin. (Shanghai) 2007, 39:869-878.
19. Hou Y., Guo T., Wu C., He X. Effect of tetrandrine combined with epirubicin on the growth of human breast carcinoma multidrug resistance cell line. Yakugaku Zasshi 2008, 128:663-666.
20. Dai C.L., Xiong H.Y., Tang L.F., Zhang X., Liang Y.J., Zeng M.S., Chen L.M., Wang X.H., Fu L.W. Tetrandrine achieved plasma concentrations capable of reversing MDR in vitro and had no apparent effect on doxorubicin pharmacokinetics in mice. Cancer Chemother Pharmacol 2007, 60:741-750.
21. Xu W.L., Shen H.L., Ao Z.F., Chen B.A., Xia W., Gao F., Zhang Y.N. Combination of tetrandrine as a potential-reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia. Leuk. Res. 2006, 30:407-413.
22. Zhu X., Sui M., Fan W. In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel. Anticancer Res. 2005, 25:1953-1962.
23. Fu L.W., Zhang Y.M., Liang Y.J., Yang X.P., Pan Q.C. The multidrug resistance of tumour cells was reversed by tetrandrine in vitro and in xenografts derived from human breast adenocarcinoma MCF-7/adr cells. Eur. J. Cancer 2002, 38:418-426.
24. Lee J.H., Kang G.H., Kim K.C., Kim K.M., Park D.I., Choi B.T., Kang H.S., Lee Y.T., Choi Y.H. Tetrandrine-induced cell cycle arrest and apoptosis in A549 human lung carcinoma cells. Int J Oncol 2002, 21:1239-1244.
25. Jin Q., Kang C., Soh Y., Sohn N.W., Lee J., Cho Y.H., Baik H.H., Kang I. Tetrandrine cytotoxicity and its dual effect on oxidative stress-induced apoptosis through modulating cellular redox states in Neuro 2a mouse neuroblastoma cells. Life Sci 2002, 71:2053-2066.
26. Kuo P.L., Lin C.C. Tetrandrine-induced cell cycle arrest and apoptosis in Hep G2 cells. Life Sci 2003, 73:243-252.
27. Wu J.M., Chen Y., Chen J.C., Lin T.Y., Tseng S.H. Tetrandrine induces apoptosis and growth suppression of colon cancer cells in mice. Cancer Lett 2009, 287:187-195.
28. Lai Y.L., Chen Y.J., Wu T.Y., Wang S.Y., Chang K.H., Chung C.H., Chen M.L. Induction of apoptosis in human leukemic U937 cells by tetrandrine. Anticancer Drugs 1998, 9:77-81.
29. Han X., Wang F., Yao W., Xing H., Weng D., Song X., Chen G., Xi L., Zhu T., Zhou J., Xu G., Wang S., Meng L., Iadecola C., Wang G., Ma D. Heat shock proteins and p53 play a critical role in K+ channel-mediated tumor cell proliferation and apoptosis. Apoptosis 2007, 12:1837-1846.
30. Gatcliffe T.A., Monk B.J., Planutis K., Holcombe R.F. Wnt signaling in ovarian tumorigenesis. Int. J. Gynecol. Cancer 2008, 18:954-962.
31. Tetsu O., McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999, 398:422-426.
32. He T.C., Sparks A.B., Rago C., Hermeking H., Zawel L., da Costa L.T., Morin P.J., Vogelstein B., Kinzler K.W. Identification of c-MYC as a target of the APC pathway. Science 1998, 281:1509-1512.
33. Easwaran V., Lee S.H., Inge L., Guo L., Goldbeck C., Garrett E., Wiesmann M., Garcia P.D., Fuller J.H., Chan V., Randazzo F., Gundel R., Warren R.S., Escobedo J., Aukerman S.L., Taylor R.N., Fantl W.J. Beta-catenin regulates vascular endothelial growth factor expression in colon cancer. Cancer Res. 2003, 63:3145-3153.
34. Fang JH F.Y. Tetrandine: pharmacology and clinical usefulness. Chin Pharmaceutic J 1996, 31.
35. Ransom C.B., Liu X., Sontheimer H. BK channels in human glioma cells have enhanced calcium sensitivity. Glia 2002, 38:281-291.
36. Lawrence T.S., Blackstock A.W., McGinn C. The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin. Radiat. Oncol. 2003, 13:13-21.
37. Lin Y.G., Kunnumakkara A.B., Nair A., Merritt W.M., Han L.Y., Armaiz-Pena G.N., Kamat A.A., Spannuth W.A., Gershenson D.M., Lutgendorf S.K., Aggarwal B.B., Sood A.K. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res 2007, 13:3423-3430.
38. Badiglian Filho L., Oshima C.T., De Oliveira Lima F., De Oliveira Costa H., De Sousa Damiao R., Gomes T.S., Goncalves W.J. Canonical and noncanonical Wnt pathway: a comparison among normal ovary, benign ovarian tumor and ovarian cancer. Oncol Rep 2009, 21:313-320.
39. Dissanayake S.K., Wade M., Johnson C.E., O'Connell M.P., Leotlela P.D., French A.D., Shah K.V., Hewitt K.J., Rosenthal D.T., Indig F.E., Jiang Y., Nickoloff B.J., Taub D.D., Trent J.M., Moon R.T., Bittner M., Weeraratna A.T. The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition. J Biol Chem 2007, 282:17259-17271.
40. Chen Y., Chen J.C., Tseng S.H. Tetrandrine suppresses tumor growth and angiogenesis of gliomas in rats. Int J Cancer 2009, 124:2260-2269.
41. Chen X.S., Bao M.H., Mei X.D. Reversing multidrug resistance of epidermoid carcinoma drug-resistant cell line KB-MRP1 by tetrandrine. Ai Zheng 2007, 26:846-850.
42. Liu Z.L., Hirano T., Tanaka S., Onda K., Oka K. Persistent reversal of P-glycoprotein-mediated daunorubicin resistance by tetrandrine in multidrug-resistant human T lymphoblastoid leukemia MOLT-4 cells. J Pharm Pharmacol 2003, 55:1531-1537.
43. Choi S.U., Park S.H., Kim K.H., Choi E.J., Kim S., Park W.K., Zhang Y.H., Kim H.S., Jung N.P., Lee C.O. The bisbenzylisoquinoline alkaloids, tetrandine and fangchinoline, enhance the cytotoxicity of multidrug resistance-related drugs via modulation of P-glycoprotein. Anticancer Drugs 1998, 9:255-261.
44. Fu L., Liang Y., Deng L., Ding Y., Chen L., Ye Y., Yang X., Pan Q. Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Chemother. Pharmacol. 2004, 53:349-356.